The AI Platform for BioPharma Knowledge Work
Domain-specific AI for BioPharma consultants, investors, and in-house teams — reduce manual work and make better decisions
Book a DemoTrusted by world-class BioPharma teams
Smart Tables
Craft custom data tables quickly with expert-crafted Analysis Blueprints and AI-driven columns.
Build with Smart Tables
70+ Expert Vetted Table Blueprints
Catalyst Calendar
Regulatory MilestonesTop three announced catalysts in the next 12 months with expected timing.
Catalyst Calendar
Regulatory MilestonesTop three announced catalysts in the next 12 months with expected timing.
Oncology Efficacy Read-out
Clinical Outcomes & SafetyORR, mPFS, mOS, DoR split by ITT vs biomarker+; interim vs final data.
Lead Asset Spotlight
Clinical and Trial ProfileSingle most advanced program per company with modality, phase, and milestone.
Antibody PK & Immunogenicity
Clinical Outcomes & SafetyHalf-life, clearance, subQ bioavailability, ADA incidence and impact.
Clinical Asset Landscape
Clinical and Trial ProfileAssets by phase, most advanced candidate, and discontinued program reasons.
Unmet Need Scorecard
Disease & Epidemiology1–5 score based on outcome gaps, toxicity, and pipeline density with rationale.
Randomization Schema
Trial Design & OperationsRandomization ratio, blinding level, control type, and sample size.
Top Unpartnered Assets
Company & Business IntelligenceTop three assets with retained global rights, phase, and recent headline result.
Standard Of Care Analysis
Disease & EpidemiologyFirst/second-line SoC therapies and key US/EU guideline details.
Catalyst & Timeline Extractor
Regulatory Updates and MilestonesUp to five development or corporate catalysts pulled from public documents.
Cell Therapy CMC Risk Profiling
Clinical Outcomes & SafetyCell source, vein‑to‑vein time, cryochain requirements, batch failure rates.
Epidemiologic Data Extract
Disease & Epidemiology2×2 counts, effect estimates, and diagnostic metrics from association studies.
Catalyst Calendar
Regulatory MilestonesTop three announced catalysts in the next 12 months with expected timing.
Oncology Efficacy Read-out
Clinical Outcomes & SafetyORR, mPFS, mOS, DoR split by ITT vs biomarker+; interim vs final data.
Lead Asset Spotlight
Clinical and Trial ProfileSingle most advanced program per company with modality, phase, and milestone.
Antibody PK & Immunogenicity
Clinical Outcomes & SafetyHalf-life, clearance, subQ bioavailability, ADA incidence and impact.
Clinical Asset Landscape
Clinical and Trial ProfileAssets by phase, most advanced candidate, and discontinued program reasons.
Unmet Need Scorecard
Disease & Epidemiology1–5 score based on outcome gaps, toxicity, and pipeline density with rationale.
Randomization Schema
Trial Design & OperationsRandomization ratio, blinding level, control type, and sample size.
Top Unpartnered Assets
Company & Business IntelligenceTop three assets with retained global rights, phase, and recent headline result.
Standard Of Care Analysis
Disease & EpidemiologyFirst/second-line SoC therapies and key US/EU guideline details.
Catalyst & Timeline Extractor
Regulatory Updates and MilestonesUp to five development or corporate catalysts pulled from public documents.
Cell Therapy CMC Risk Profiling
Clinical Outcomes & SafetyCell source, vein‑to‑vein time, cryochain requirements, batch failure rates.
Epidemiologic Data Extract
Disease & Epidemiology2×2 counts, effect estimates, and diagnostic metrics from association studies.
Report Builder
Accelerate your research with deep analysis backed by extensive research and our proprietary citation processing pipeline.
Build with Report Builder
40+ Expert Vetted Report Blueprints
Deal Rationale One‑Pager
Corporate & OperationalStrategic fit, financial headroom, capabilities, and risks for a potential deal.
Deal Rationale One‑Pager
Corporate & OperationalStrategic fit, financial headroom, capabilities, and risks for a potential deal.
Asset Screening Memo
Portfolio & Asset StrategyEarly‑stage asset go/no‑go: biology, comps, feasibility, and risk score.
Guideline‑Shift Impact
Market Access & CommercialHow new society guidelines alter sequencing, payer stance, and competition.
Trial Failure Root‑Cause
Clinical & Scientific StrategyDissects design, biology, ops, and stats behind high‑profile trial failures.
White‑Space Indication Scan
Portfolio & Asset StrategyPrioritizes three new indications via mechanistic, epi, and commercial filters.
US Pricing Analogues
Market Access & CommercialLaunch metrics and net‑price history to guide WAC/NDC planning.
Platform‑Technology Explainer
Corporate & OperationalTranslates a platform's mechanism, assets, CMC needs, comps, and PoC milestones.
Real‑World‑Evidence Round‑up
Clinical & Scientific StrategySynthesizes RWE on durability, adherence, effectiveness, and study caveats.
KOL Landscape Narrative
Patient & StakeholderProfiles, networks, and influence of thought leaders to guide engagement.
Regulatory Pathway Storyboard
Market Access & CommercialStepwise submission strategy, designations, agency touchpoints, and PMRs.
Safety Signal Surveillance
Clinical & Scientific StrategyRecent post‑marketing signals, plausibility, regs comms, and mitigation tactics.
Trial‑Design Critique
Clinical & Scientific StrategyPivotal trial deep dive: schema, endpoints, stats plan, ops issues, implications.
Deal Rationale One‑Pager
Corporate & OperationalStrategic fit, financial headroom, capabilities, and risks for a potential deal.
Asset Screening Memo
Portfolio & Asset StrategyEarly‑stage asset go/no‑go: biology, comps, feasibility, and risk score.
Guideline‑Shift Impact
Market Access & CommercialHow new society guidelines alter sequencing, payer stance, and competition.
Trial Failure Root‑Cause
Clinical & Scientific StrategyDissects design, biology, ops, and stats behind high‑profile trial failures.
White‑Space Indication Scan
Portfolio & Asset StrategyPrioritizes three new indications via mechanistic, epi, and commercial filters.
US Pricing Analogues
Market Access & CommercialLaunch metrics and net‑price history to guide WAC/NDC planning.
Platform‑Technology Explainer
Corporate & OperationalTranslates a platform's mechanism, assets, CMC needs, comps, and PoC milestones.
Real‑World‑Evidence Round‑up
Clinical & Scientific StrategySynthesizes RWE on durability, adherence, effectiveness, and study caveats.
KOL Landscape Narrative
Patient & StakeholderProfiles, networks, and influence of thought leaders to guide engagement.
Regulatory Pathway Storyboard
Market Access & CommercialStepwise submission strategy, designations, agency touchpoints, and PMRs.
Safety Signal Surveillance
Clinical & Scientific StrategyRecent post‑marketing signals, plausibility, regs comms, and mitigation tactics.
Trial‑Design Critique
Clinical & Scientific StrategyPivotal trial deep dive: schema, endpoints, stats plan, ops issues, implications.
Maven Assistant
Get instant answers to BioPharma questions, with direct links to primary sources. Answers grounded in the latest information from Maven Bio's curated database of BioPharma industry knowledge.
Get clarity with Maven Assistant
Maven Watchlists
Monitor companies, trials, and events—enhanced by personalized context and AI-driven insights tailored specifically to your strategic context.
Monitor with Maven Watchlists
Market Screening
Rapidly pinpoint drugs, companies, trials, mechanisms, or targets matching your specific criteria.
Start Screening
Clinical Data Benchmarking
Robustly benchmark clinical trials and generate intuitive, evidence-backed insights customized for your focus area.
Benchmark Clinical Data
Unlock purpose-built AI research for your team
Stop burning hours on manual data hunts — let Maven Bio do the heavy lifting so you can focus on the strategic decisions that drive your business forward.
Schedule a Demo